13-deoxydoxorubicin
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 1999 (NCT00003403)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(CCO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1- Mol. weight
- 529.54 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3249110 ↗
Also known as
- 13-deoxydoxorubicin
- 13-deoxydoxorubicin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00123877 | Phase 2 | Mar 1, 2005 | Gem Pharmaceuticals, University of Utah |
| NCT00003403 | Phase 1 | Aug 1, 1999 | Gem Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gem Pharmaceuticals | For profit | 2 | 2 | 2 | 1999 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1